Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Nan Jing, China Clinical Trials

A listing of Nan Jing, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (420) clinical trials

Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)

This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin) Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad of population of children.

Phase

0.0 miles

Learn More »

Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

The purpose of this single arm study is to assess the safety and efficacy of ATAN (Apatinib) in patients with Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction in clinical practice. ATAN will be given to patients who had failed at least two lines of prior chemotherapy. Eligible ...

Phase

0.0 miles

Learn More »

Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for Diagnosis of Hepatic Steatosis

This will be a multi-center, prospective, controlled study. It is expected that about 240 subjects from 10 study centers will be enrolled, and 224 effective subjects will be statistically analyzed in the end, in which 56 effective subjects with stage F0 (25%), 56 effective subjects with stage F1 (25%), 56 ...

Phase N/A

0.0 miles

Learn More »

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.

Phase

0.0 miles

Learn More »

FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis

The liver diseases frequently occur in China. For various reasons, the chronic liver diseases are not controlled in time, and then develop gradually into liver fibrosis and cirrhosis. Without effective treatment, the advanced liver cirrhosis seriously influences the quality of patients' life, and places an intolerable burden on family and ...

Phase N/A

0.0 miles

Learn More »

FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer

Endostar is free supported by Shangdong Simcere Medgene biotech co.,Ltd. Endostar combination with Chemotherapy has been the first line treatment regimen to advanced NSCLC. Clinical data proved that Endostar was a wild spectrum and safe antiangiogenesis factor which could suppress almost 65 kinds of tumor mass in animal models and ...

Phase

0.0 miles

Learn More »

Study of the Pathogenesis and Molecular Mechanism of "YURE" in Internal Intractable Diseases

Blood stasis and blood heat are two pathogens in the theory system of Chinese Medicine, which can cause many diseases independently. But in internal intractable diseases, such as viral hepatitis, stroke, and epidemic hemorrhagic fever, blood stasis and blood heat always accompany with each other. So the hypothesis is raised ...

Phase

0.0 miles

Learn More »

The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial

The efficacy and safety of Butylphthalide Soft Capsules (En Bi Pu, NBP)in acute ischemic stroke has been demonstrated in China recently. Its role in secondary prevention of ischemic stroke need to be evaluated.

Phase

0.0 miles

Learn More »

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

This is a single arm, open label study, including phase I (a "dose escalation" part and a "dose extension" part) and phase IIa. Dose escalation: on the basis of the traditional "3+3" dose escalation plan; single dose PK test is added. The subjects of each dose group will first be ...

Phase

0.0 miles

Learn More »

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation

Participants considered an adult according to local regulations at the time of signing informed consent will be randomized in a 1:1 ratio to receive ASP2215 or salvage chemotherapy. Participants will enter the screening period up to 14 days prior to the start of treatment. Prior to randomization, the investigator will ...

Phase

0.0 miles

Learn More »